(PDF) Impact of Switching From Epoprostenol to IV

Impact of Switching From Epoprostenol to IV Treprostinil on Treatment Satisfaction and Quality of Life in Patients With Pulmonary Hypertension

Respiratory Medicine - United Kingdom

doi 10.1016/j.rmed.2012.10.023

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

March 1, 2013

Authors

Publisher

Elsevier BV

Related search

Treatment Satisfaction Is Associated With Improved Quality of Life in Patients Treated With Inhaled Treprostinil for Pulmonary Arterial Hypertension

Health and Quality of Life Outcomes

Occupational Health

English

Prs9 - Switching From Subcutaneous Treprostinil to Inhaled Treprostinil in Pulmonary Arterial Hypertension Treatment and Economic Impact Evaluation

Value in Health

Occupational Health

English

Transition of Stable Pediatric Patients With Pulmonary Arterial Hypertension From Intravenous Epoprostenol to Intravenous Treprostinil

American Journal of Cardiology

Cardiovascular Medicine

English

Epoprostenol Treatment in Children With Severe Pulmonary Hypertension

Cardiovascular Medicine

English

Rapid Transition From Inhaled Iloprost to Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension

Cardiovascular Therapeutics

Cardiovascular Medicine

English

Treatment Satisfaction and Quality of Life in Patients Treated With Fingolimod

Patient Preference and Adherence

Social Sciences

English

Epoprostenol Treatment for Idiopathic Pulmonary Arterial Hypertension in Pregnancy

Journal of Perinatology

English

Quality of Life in Pulmonary Arterial Hypertension: Qualitative Insights From Patients and Caregivers

Advances in Pulmonary Hypertension

English

Tolerability and Clinical Efficacy of Inhaled Treprostinil in Patients With Group 1 Pulmonary Arterial Hypertension

Therapeutic Advances in Chronic Disease

English